Ganymede Bio

Ganymede Bio is a cloud infrastructure and data platform company serving life sciences research, development and manufacturing. Its platform connects laboratory instruments, scientific applications (ELN, LIMS, MES/LES, QMS), data pipelines and third-party partners such as CROs and CDMOs into a single cloud data layer, standardizing and unifying both dry and wet lab data according to FAIR principles (findable, accessible, interoperable, reusable). The company describes hundreds of pre-built connectors plus tooling for customers to build their own integrations.

The core technology is marketed as "Lab-as-Code": scientists and bioinformaticians write real-time integrations and analysis in Python/SQL through a low-code, flow-based web IDE, with pipeline code, scheduling and notification configuration versioned in a backing Git repository and execution occurring in versioned Docker containers for traceability. Additional modules include unified dashboards over structured lab data, a versioned FAIR data cloud with file tagging and code lineage, remote instrument data capture and monitoring, and virtualization that runs scientific applications, VMs or virtual desktops in the browser so analysis can move off lab PCs. Modular Analysis packages automated analytics for workflows such as bioprocess optimization and DOE, chromatography control charts and cross-batch modeling, liquid handler utilization and error analysis, and plate-based assay curve fitting.

The platform is positioned as infrastructure-agnostic, integrating natively with existing AWS, GCP or Azure environments and with tools such as Benchling, and is aimed at making lab data visible to management and analysis-ready for machine learning and digital twins. Ganymede also provides end-to-end enterprise services and custom integration builds. In January 2026, Apprentice.io announced its acquisition of Ganymede.

Founding story

Ganymede Bio was founded in 2022 by a team including CEO and co-founder Nathan Clark and founding scientist Alan Chramiec, Ph.D. The founding team's experience spans machine learning, financial services, life sciences, automation and robotics, consumer technology and biomedical research, and the company framed its premise around scientific software being 10 to 20 years behind other industries.

Business model

Ganymede sells a modular, multi-tenant cloud data platform to life science organizations, complemented by end-to-end enterprise services and custom integration development for clients. Prospects are converted through demo requests, and the platform is designed to be adopted module by module alongside a customer's existing cloud and software investments.

Commercial software sold to biotech, pharmaceutical and diagnostics organizations, with additional revenue from enterprise services and custom integrations; the company reported exceeding $1 million in revenue commitments as of December 2022.

Traction

As of the December 2022 Series A announcement, Ganymede had exceeded $1 million in revenue commitments with clients ranging from early-stage biotechs to large biopharmaceutical companies. Customer-reported outcomes cited by the company include two months faster scale-up for a cell therapy bioprocess client, roughly 2,500 hours saved annually by automating peak finding with AI for an analytical chemistry team, and a 60% throughput increase for plate-based assays at a diagnostics client; Solugen reported a 10x increase in sample throughput.

Latest developments

Apprentice.io announced on January 21, 2026 that it had acquired Ganymede, and Ganymede's website now states that Ganymede is part of Apprentice.io. Shortly before that, in August 2025, Ganymede launched a scientific AI agent platform targeting process development, R&D and manufacturing.